Credit Suisse Group restated their neutral rating on shares of AstraZeneca plc (LON:AZN) in a report issued on Monday. They currently have a GBX 4,700 ($60.70) target price on the biopharmaceutical company’s stock.
Several other analysts also recently issued reports on the company. Liberum Capital reiterated a buy rating and set a GBX 4,800 ($61.99) price target on shares of AstraZeneca plc in a research note on Monday. J P Morgan Chase & Co reiterated a neutral rating and set a GBX 4,200 ($54.24) price target on shares of AstraZeneca plc in a research note on Friday. Citigroup Inc. reiterated a buy rating on shares of AstraZeneca plc in a research note on Thursday, September 7th. Natixis upgraded AstraZeneca plc from a neutral rating to a buy rating and upped their price target for the stock from GBX 5,000 ($64.57) to GBX 5,738 ($74.11) in a research note on Wednesday, September 6th. Finally, Deutsche Bank AG reiterated a buy rating and set a GBX 5,300 ($68.45) price target on shares of AstraZeneca plc in a research note on Tuesday, September 5th. Three analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of Hold and an average target price of GBX 4,963.82 ($64.11).
AstraZeneca plc (LON AZN) opened at 4900.50 on Monday. The firm’s market capitalization is GBX 62.04 billion. The company’s 50-day moving average price is GBX 4,571.40 and its 200 day moving average price is GBX 4,878.32. AstraZeneca plc has a 52-week low of GBX 3,996.00 and a 52-week high of GBX 5,520.00.
AstraZeneca plc (LON:AZN) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $0.85 by $1.01. AstraZeneca plc had a return on equity of 14.36% and a net margin of 8.83%. Equities research analysts predict that AstraZeneca plc will post $3.75 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (AZN) Given “Neutral” Rating at Credit Suisse Group” was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/09/12/astrazeneca-plc-azn-given-neutral-rating-at-credit-suisse-group.html.
The business also recently announced a dividend, which was paid on Monday, September 11th. Stockholders of record on Thursday, August 10th were issued a GBX 68.90 ($0.89) dividend. The ex-dividend date was Thursday, August 10th. This represents a dividend yield of 1.35%.
In related news, insider Nazneen Rahman bought 39 shares of the company’s stock in a transaction dated Thursday, July 27th. The stock was acquired at an average cost of GBX 4,370 ($56.44) per share, with a total value of £1,704.30 ($2,201.08).
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.